Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PARL | Q9H300 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108464 | 1.00 | TSHR (0.39) | TSHRMGLLNFKB1CYP2C19ALDH1A1 | |
| SCHEMBL20404645 | 0.92 | MGLL (0.36) | MGLLPARL | |
| SCHEMBL111364 | 0.92 | MGLL (0.36) | MGLLPARL | |
| SCHEMBL37884 | 0.92 | MGLL (0.36) | MGLLPARL | |
| SCHEMBL23584357 | 0.81 | MGLL (0.32) | MGLL | |
| SCHEMBL13286374 | 0.81 | MGLL (0.32) | MGLL | |
| SCHEMBL13286350 | 0.81 | MGLL (0.32) | MGLL | |
| SCHEMBL4003476 | 0.81 | MGLL (0.33) | MGLL | |
| SCHEMBL4003479 | 0.81 | MGLL (0.33) | MGLL | |
| SCHEMBL2573222 | 0.79 | MGLL (0.36) | MGLLPARL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-03-12 | — | — | US | claimed |
| CN-110420671-A | A kind of agglutinin micro-array chip and preparation method thereof | NANJING KERUIXIN BIO TECH CO LTD | 2019-11-08 | — | — | CN | claimed |
| CN-102666879-B | Templated nanometer conjugate | NORTHWEST UNIVERSITY (US) | 2016-02-24 | — | — | CN | claimed |
| CN-102666879-A | Templated nanoconjugates | UNIV NORTHWESTERN | 2012-09-12 | — | — | CN | claimed |
| CN-101405301-A | Conjugates comprising pharmacologically active compounds covalently linked to mucoadhesive polymers and methods of transmucosal administration of pharmacologically active compounds using the same | KWANGJU INST SCI & TECH (KR) | 2009-04-08 | — | — | CN | claimed |
| CN-101039965-A | Sialic acid derivatives | LIPOXEN TECHNOLOGIES LTD (GB) | 2007-09-19 | — | — | CN | claimed |
| CN-87103784-A | IMMUNOPOTATION | — | 1987-12-09 | — | — | CN | claimed |
| US-20260077088-A1 | SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES | CRANNMED LIMITED (IE) | 2026-03-19 | — | — | US | disclosed |
| EP-4583839-A1 | SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES | Crannmed Limited (IE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025137256-A1 | POLYOXAZOLINE-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250099480-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD | CORMEDIX INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12016865-B2 | Methods and pharmaceutical compositions for treating candida auris in blood | CORMEDIX INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024052780-A1 | SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES | CRANNMED LIMITED (IE) | 2024-03-14 | — | — | WO | disclosed |
| US-5241012-A | Nitrated, reduced to amine, diazotization to link with protein ; electrophilic substitution | APPLIED IMMUNE SCIENCES, INC. (US) | 1993-08-31 | — | — | US | disclosed |
| US-5045312-A | Complexing | BURROUGHS WELLCOME CO. (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0377649-A1 | HALOGENATED SURFACE WITH REDUCED PROTEIN INTERACTION. | HEWLETT PACKARD CO (US) | 1990-07-18 | — | — | EP | disclosed |
| WO-1989012225-A1 | HALOGENATED SURFACE WITH REDUCED PROTEIN INTERACTION | HEWLETT-PACKARD COMPANY (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0294059-A2 | Activated and conjugated polyaryl substrates | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1988-12-07 | — | — | EP | disclosed |
| CN-87102945-A | Pre-S gene coded peptide hepatilis B immunogens, vaccine, diagnostic agent and synthetic lipid vesicle carriers | — | 1988-04-20 | — | — | CN | disclosed |
| CN-87103784-A | IMMUNOPOTATION | — | 1987-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200080122-A1 | Cleavable Nucleotide Analogs and Uses Thereof | TYMP, DUT, NT5C3B | TSHR 2802/4885MGLL 4064/4885NFKB1 2847/4885 |
| US-20260077088-A1 | SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES | MMP2, PLG, PMM2 | TSHR 1647/4885MGLL 607/4885NFKB1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.